Open access
Open access
Powered by Google Translator Translator

Daily Archives: May 17, 2018

Thu, May 17 – 10 Stories of The Day!

17 May, 2018 | 01:41h | UTC

 

#ESOC2018 – Highlights from the 4th European Stroke Organization Conference

 

1 – #ESOC2018 – Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial – The Lancet (free)

Editorial: Haemostatic treatment for intracerebral haemorrhage (free)

Commentaries: Study: Drug to treat bleeding may reduce stroke deaths – UPI (free) AND Drug to treat bleeding may benefit some stroke patients, study finds – University of Nottingham, via EurekAlert (free)

 

2 – #ESOC2018 – Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA – New England Journal of Medicine (free)

Editorial: Antiplatelet Therapy after Ischemic Stroke or TIA (free)

Commentary: Dual Antiplatelet Therapy or Aspirin Alone After TIA or Minor Stroke? – NEJM Physician’s First Watch (free)

 

3 – #ESOC2018 – MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset – New England Journal of Medicine (free)

Editorial: MRI-Guided Intravenous Alteplase for Stroke — Still Stuck in Time (free)

Commentary: New treatment option for ‘wake-up’ stroke patients – University of Glasgow, via MedicalXpress (free)

 

4 – #ESOC2018 – Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source – New England Journal of Medicine (free)

Commentaries: NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin – TCTMD (free) AND Rivaroxaban Not Superior to Aspirin for Patients with Embolic Stroke of Unknown Source – NEJM Physician’s First Watch (free)

 

5 – #ESOC2018 – Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke – New England Journal of Medicine (free)

Commentaries: Elevated Stroke Risk Continues for 5 Years After TIA – NEJM Physician’s First Watch (free) AND Five Years after TIA or Minor Stroke, Second-Event Risk Persists – MedPage Today (free)

 

6 – Manual: Managing epidemics: Key facts about major deadly diseases – World Health Organization (free)

“Managing epidemics. This @WHO manual provides concise, up-to-date knowledge on 15 infectious diseases that have the potential to become international threats, and tips on how to respond to each of them”. (via @Onisillos and @claireekt see Tweet)

 

7 – Report: Saving lives, spending less: a strategic response to noncommunicable diseases – World Health Organization (free PDF)

News Release: Investing in noncommunicable disease control generates major financial and health gains – World Health Organization (free)

“For every US$1 invested in each policy area, the following returns have been documented:

US$12.82 from promoting healthy diets

US$9.13 from reducing the harmful use of alcohol

US$7.43 from lower tobacco use

US$3.29 from providing drug therapy for cardiovascular disease

US$2.80 from increasing physical activity

US$2.74 from managing cancer”

 

8 – ASCO 2018: Shortening Adjuvant Trastuzumab to 6 Months in Patients With HER2-Positive Early Breast Cancer Is Effective and Reduces Cardiac Toxicities – The ASCO Post (free)

Commentaries: Test of Herceptin Finds Briefer Treatment Can Work, With Fewer Side Effects – NPR (free) AND Shorter drug treatment OK for many breast cancer patients – Associated Press (free) AND For Women With Early Breast Cancer, Herceptin Treatment Can Be Much Shorter – The New York Times (10 articles per month are free)

““For women with early-stage breast cancer who needed the drug Herceptin, 6 months of treatment were as good as 12, a major study found. Less risk of side effects, less cost, less time “being a patient.”” (via @NYTHealth see Tweet)

 

9 – Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016 – JAMA Oncology (free)

“Global incident cases of multiple myeloma more than doubled from 1990-2016 w/incident cases increasing by 126%. The largest increase was in middle-SDI countries, particularly E. Asia with a 262% increase in incidence cases”. (via @IHME_UW see Tweet)

 

10 – Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women—A double-blind, randomized non-inferiority trial – PLOS Medicine (free)

Commentary: Ibuprofen alone not an option for simple UTIs, study finds – CIDRAP (free) AND Randomized trial finds ibuprofen not a safe alternative to antibiotics for UTIs – PLOS, via ScienceDaily (free)

Related Research: Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial- The BMJ (free)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.